Esketamine Effective and Costly Treating Treatment-Resistant Depression

Mclean Hospital

HCP Live

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

Read Full Article

Topics

Depression Ketamine

McLean Main Navigation

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

HCP Live

Planning Can Help Our Mental Well-Being

What’s Preventing Asian Americans From Seeking Mental Health Care?

Can We Control Our Anxiety and Keep It From Controlling Us?

The Importance of Gratefulness

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

HCP Live

You May Also Like

Ketamine for Depression Still Too Expensive for Widespread Use

The Benefits of Taking a Mental Health Day

Study Examines the Cost-Effectiveness of Esketamine

Ketamine – The Good, The Bad, The Future of Treating Depression?

Resources

Latest Videos

Planning Can Help Our Mental Well-Being

What’s Preventing Asian Americans From Seeking Mental Health Care?

Can We Control Our Anxiety and Keep It From Controlling Us?

The Importance of Gratefulness

Keep Up With McLean!